Source link : https://www.newshealth.biz/health-news/upadacitinib-effective-for-rare-disorder-in-case-series/
TOPLINE: Upadacitinib, an oral Janus kinase (JAK) 1 inhibitor, showed an 80% complete response rate in patients with granulomatous cheilitis, with no serious adverse events, in a small retrospective case series. METHODOLOGY: Granulomatous cheilitis is a rare, non-necrotizing granulomatous inflammatory disorder characterized by intermittent or persistent swelling of the lips. In a retrospective case series […]
Author : News Health
Publish date : 2024-08-02 06:09:54
Copyright for syndicated content belongs to the linked Source.
Categories